A Study of MT027 in Patients with Pleural Malignant Tumors

This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who have previously received standard of care therapy.. Subjects meeting the study entry criteria including having tumor antigen B7H3 overexpression via immunohistochemistry (IHC ) will be enrolled and assigned to cohorts sequentially to receive study treatments, assessments, as well as post-treatment safety follow-ups in the study.

Trial Details

NCT ID
NCT06726564
Phase
PHASE1
Sponsor
Suzhou Maximum Bio-tech Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • MT027 cells suspension
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • voluntarily participate in the study and sign informed consent;
  • age over 18 years old (including the cut-off value), regardless of gender;
  • advanced malignant solid tumor pathologically and/or histologically diagnosed with malignant pleural effusion requiring drainage confirmed by histo…
  • the original pleural cavity malignant tumor after standard treatment failure, or top treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →